Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as it is launching several new blockbusters and patent losses are fading.
Lilly's strong leadership in weight-loss drugs should drive industry-leading growth, given its approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.
The risks to success for Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition.
|
Metric
|
LLY
|
NVO
|
BMY
|
|---|---|---|---|
Price/Earnings (Normalized) | 38.91 | 10.46 | 9.56 |
Price/Book Value | 32.78 | 6.01 | 5.75 |
Price/Sales | 14.23 | 3.69 | 2.38 |
Price/Cash Flow | 38.26 | 9.18 | 7.83 |
|
Metric
|
LLY
|
NVO
|
BMY
|
|---|---|---|---|
Quick Ratio | 0.72 | 0.54 | 1.18 |
Current Ratio | 1.50 | 0.79 | 1.42 |
Interest Coverage | — | — | 6.31 |
|
Metric
|
LLY
|
NVO
|
BMY
|
|---|---|---|---|
Return on Assets (Normalized) | 24.73% | 22.35% | 13.15% |
Return on Equity (Normalized) | 114.33% | 66.15% | 65.90% |
Return on Invested Capital (Normalized) | 40.96% | 37.39% | 19.89% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Johnson & Johnson
JNJ
| Pvsnpzptj | Msrgt | $571B | |||
| AbbVie Inc
ABBV
| Ftyrpzrh | Pdcpv | $397B | |||
| Roche Holding AG ADR
RHHBY
| Kdlxqxzb | Hzkv | $323B | |||
| Merck & Co Inc
MRK
| Qbfpystcq | Ytlwp | $295B | |||
| Novartis AG ADR
NVS
| Cwvmfbgtjl | Wmbxc | $284B | |||
| AstraZeneca PLC
AZN
| Xjcljcfx | Pbh | $279B | |||
| Amgen Inc
AMGN
| Gjnwqvgck | Tmvb | $186B | |||
| Novo Nordisk AS ADR
NVO
| Qjlrhnbr | Njvq | $184B | |||
| Gilead Sciences Inc
GILD
| Lrbyjvrj | Lzjtd | $156B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
United States